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1607-551X/Copyright ª 2016, Kaohsiu
CC BY-NC-ND license (http://creativAbstract To investigate the influence of different menstrual phases on the Bispectral Index
(BIS) during dexmedetomidine (Dex) sedation, 40 patients with regular menstrual cycle, Amer-
ican Society of Anesthesiologists IeII, aged 18e40 years, undergoing selective gynecologic
laparoscopic surgery, were enrolled. According to different menstrual phases and the serum
progesterone concentration, they were divided into two groups: the follicular phase group
(Group F) and the luteal phase group (Group L), and each group had 20 patients. Before anes-
thesia induction, patients were infused with an initial loading dose of Dex (1 mg/kg) for 10 mi-
nutes and then 0.5 mg/kg/h for 20 minutes. BIS and the changes in hemodynamic and
respiratory parameters were recorded within those 30 minutes. Time to lower BIS to 70 and
60 in Group L was shorter than that in Group F (9.4  1.3 minutes vs. 11.3  2.1 minutes,
p Z 0.005; 11.3  2.4 minutes vs. 14.0  3.6 minutes, p Z 0.021). The number of patients
whose BIS reached 50 in Group L was greater than that in Group F (15 vs. 8, p < 0.05). The
lowest BIS value in the Group L was lower than that in Group F (46.8  6.3 vs. 55.3  5.5,
p Z 0.006), and the heart rate of patients in both groups showed a decrease (p < 0.05).
The sedative effect of Dex was more significant in patients during the luteal phase than during
the follicular phase.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).eclare no conflicts of interest.
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Menstrual phases with dexmedetomidine sedation 587Introduction
Women have higher Bispectral Index (BIS) scores at similar
concentrations of anesthetics and emerge faster from gen-
eral anesthesia than men [1]. In recent years, there is an
increased interest in studying sex-based differences in
pharmacokinetics and pharmacodynamics [2]. Despite the
sex-based differences, different menstrual phases among
women may exert a certain influence on anesthesia. Studies
have shown that the threshold of pains is lower and post-
operative nausea and vomiting are more frequent in the
follicular phase than in the luteal phase [3,4]. It was also
reported that patients in the follicular phase needed more
sevoflurane than those in the luteal phase during the
maintenance of general anesthesia and this difference
might be caused by the increase of progesterone level in the
luteal phase, which reduced the required dosages of anes-
thetics [5]. Dexmedetomidine (Dex) is a highly selective a2-
adrenergic receptor agonist. It has been reported to provide
sedation that parallels natural sleep, anxiolysis, analgesia,
and sympatholysis, as well as an anesthetic-sparing effect
with minimal respiratory depression [6]. It is a widely used
intravenous sedative in clinical anesthesia setting. Different
from the sedative mechanism of propofol and midazolam,
Dex mainly acts on the a2-adrenoceptor of locus coeruleus
and its sedative effect is similar to that of natural sleepiness
[7]. Dex, due to its sympatholytic effects, blunts the
hyperdynamic response to laryngoscopy and surgery and
maintains a stable hemodynamic profile [8e10]. It also has
been found to potentiate the effects of all anesthetic
agents, including intravenous and inhalational agents, and
has opioid-sparing effects, thereby reducing the doses
required [11e13]. Dex has both sympatholytic effects and
anesthesia-sparing effects, thus making it an ideal candi-
date for induction and maintenance.
This prospective observational study was performed to
investigate the influence of different menstrual phases on
the Dex-sedative effect, which was assessed with BIS. The
hypothesis of our study was that for patients in the luteal
phase, intravenous administration of Dex results in an
increased sedation level, compared with patients in the
follicular phase.
Methods
This trial is registered at chictr.org.cn (Trial Registration
Number: ChiCTR-IOR-15006092) and is a prospective case-
econtrol study, which was approved by the Committee of
the Obstetrics and Gynecology Hospital, Fudan University
(Shanghai, China). Written informed consent was obtained
from all patients. Patients with American Society of Anes-
thesiologists physical status I or II, aged 18e40 years, with
body mass index 21e30 kg/m2, having regular menstrual
cycle, and undergoing selective gynecologic laparoscopic
surgery including myomectomy and oophorocystectomy
from December 2014 to January 2015 were enrolled
(N Z 40). Regular menstrual cycle is defined as menstrual
cycle lasting between 23 days and 35 days with cyclic
changes < 2 days [4]. Patients were excluded for the
following reasons: taking hormones before surgery, history
of alcoholism, antipsychotics, benzodiazepines,anticonvulsant, or opioid drugs. Menstrual cycles of all
patients were assessed by experienced gynecologists and
peripheral venous blood samples were collected in the
morning on the day of the surgery to measure the serum
progesterone and estradiol concentrations using the
chemiluminescent method. The 40 patients analyzed in this
study were divided into two groups: the follicular phase
group (Group F) and the luteal phase group (Group L).
All patients underwent routine preoperative preparation.
Solid-food intake stopped after supper the day before the
operation and all patients fasted for more than 10 hours. No
premedication was given. Upon arrival in the operating the-
ater, an intravenous line was set on the back of the left hand
for administration of Ringer’s lactate solution at 10mL/kg/h,
and standard monitoring measures were applied, including
noninvasive arterial pressure, five-lead electrocardiogram,
pulse oximetry [peripheral capillary oxygen saturation
(SpO2); Intellivue MP40, Philips, Bo¨blingen, badenia-wir-
tembergia, Germany], and BIS (BIS VISTA, Covidien, Prince-
ton, New Jersey, USA). After cleaning the forehead and
placing the BIS sensor, the electrodes were pressed for
5 seconds. The BIS was calculated with a smoothing rate of
15 seconds. While recording the BIS, movements and talks of
other staff members were forbidden. Before the induction of
anesthesia, patientswere required to close their eyes,wore a
four-tailed mask to take in oxygen (6 L/min), and connected
to the anesthesia machine (S/5 Avance, Datex-Ohmeda, Inc.,
Madison, Wisconsin, USA). Dex (4 mg/mL; dexmedetomidine
hydrochloride injection, No. 14092732; Hengrui Medicine
Co., Ltd, Lianyungang, Jiangsu, China) was prepared using
normal sodiumchloride injection. Patientswere continuously
infused initially with a Dex loading dose of 1 mg/kg for
10minutes and then received 0.5 mg/kg/h Dex for 20minutes
via an infusion pump (Agilia, Fresenius Kabi, Bad Homburg,
Baden-Wu¨rttemberg, Germany). The anesthetists and data
recorder were all blind to the menstrual phases of the pa-
tients. Following the infusion of Dex, propofol was adminis-
tered via an infusion pump (Agilia, Fresenius Kabi, Bad
Homburg, Baden-Wu¨rttemberg, Germany), simulating Marsh
pharmacokinetic model with a target plasma concentration
set at 4.0 mg/mL; then, fentanyl (3 mg/kg) was administered
intravenously. After loss of consciousness, rocuronium
(0.8 mg/kg) was used for neuromuscular relaxation. Ninety
seconds later, tracheal intubation was performed.
The primary outcome measure was the time at which the
BIS score decreased to 70 and 60. The secondary outcome
measures were heart rate (HR), systolic blood pressure
(SBP), diastolic blood pressure (DBP), pulse oxygen satura-
tion (SpO2), respiratory rate (RR), and end-tidal CO2 pres-
sure (PetCO2), which were recorded before the loading
dose (T0) and 5 minutes (T5min), 10 minutes (T10min),
15 minutes (T15min), 20 minutes (T20min), 25 minutes
(T25min), and 30 minutes (T30min) after starting Dex infusion.
We also recorded the occurrence, if any, of hyperten-
sion, hypotension, bradycardia, apnea after infusion of
Dex. Hypertension is defined as an increase of SBP by over
20% of the normal value; hypotension is defined as a
decrease of SBP by over 20% of the normal value or SBP
lower than 90 mmHg; serious bradycardia is defined as a
decrease of HR by over 30% of the normal value or lower
than 45 beats/min; and apnea is defined as the stop of
spontaneous breathing longer than 20 seconds according to






Age (y) 32.5  5.2 33.7  6.0 0.503
Height (cm) 160.6  4.9 160.4  5.5 0.904








0.7  0.2 9.8  3.5 <0.001
Basic value of
Bispectral Index
97.5  0.8 97.5  0.9 0.78
a Compared with the follicular group.
588 C. Han et al.the changes of RR and PetCO2. Patients with serious
bradycardia would be immediately infused intravenously
with atropine (0.01 mg/kg) until their HR increased to
50 beats/min. If hypotension persisted, phenylephrine
(0.1 mg) was infused every 5 minutes to restore SBP to at
least 80% of the normal value. If apnea occurred, a skilled
anesthesiologist would support the submaxilla to keep the
respiratory tract unblocked.
According to our preliminary study, the standard devia-
tion of the time required for decreasing the BIS to 60 was
2.9 minutes in 15 patients. The expected clinical difference
was about 3 minutes between two groups. We calculated
that 20 patients in each group would be required (aZ 0.05,
b Z 0.1).
Statistical analysis was performed using SPSS version
19.0 for Windows (SPSS Inc., Chicago, IL, USA). Measure-
ment data were expressed by mean and standard deviation
(mean  standard deviation). Enumeration data including
incidence of hypertension, hypotension, apnea, and
bradycardia were compared with c2 analysis or Fisher’s
exact test. One-way analysis of variance with post hoc
Dunnett analysis was used for data measurement within
each group. Continuous variables were compared between
the groups using analysis of variance with post hoc Bon-
ferroni test. For all observations, the level of significance
was accepted as aZ 0.05. All p values lower than or equal
to this level were considered statistically significant.Figure 1. CONSORTResults
Forty patients were included in the final analysis (Figure 1).
Characteristics of study patients are presented in Table 1.
There were no statistical differences in terms of age,
height, weight, basic value of BIS, and the estradiol level
among patients from the two groups (p > 0.05). However,2010 flow diagram.
Menstrual phases with dexmedetomidine sedation 589the mean progesterone level in Group L patients was
dramatically higher than that in Group F patients
(p < 0.05).
Compared with the basic values (T0), HR of both groups
declined remarkably after the infusion of Dex (p < 0.05).
Changes in SBP and DBP were not significantly different
between the two groups (p > 0.05, Table 2).
The differences in respiratory parameters between the
two groups after the infusion of Dex did not show any sta-
tistical significance (p > 0.05, Table 3).
The time taken for the BIS value to decrease to 70
(9.4  1.3 minutes vs. 11.3  2.1 minutes, p < 0.001) and
60 (11.3  2.4 minutes vs. 14.0  3.6 minutes, p Z 0.021)
was significantly shorter in Group L than that in Group F.
The number of patients whose BIS could reach 50 in Group L
was significantly more than that in Group F (15 vs. 8,
p < 0.05). The lowest BIS values in Group L were lower than
those in Group F (46.8  6.3 vs. 55.3  5.5, p < 0.001, Table
4).
The incidence of serious bradycardia did not have any
significant difference after the infusion of Dex in the two
groups (15% vs. 10%, p > 0.05), and the HR of all patients
recovered to 50 beats/min after intravenous infusion of
atropine. No patients in either group had hypertension,
hypotension, or apnea during the study.Discussion
Dex, a highly selective a2-adrenergic receptor agonist, in-
hibits the activities of noradrenergic neurons in the locus
coeruleus of the brain, a key part controlling waking and
sleeping, and induces a sedative hypnotic effect
like sleeping [7]. Dex with its sedative, analgesic, andTable 2 Hemodynamic changes in the two groups.
Group F (N Z
Systolic blood pressure (mmHg) T0 115.9  9.
T5 114.8  10
T10 113.6  9.
T15 110.8  12
T20 110.8  9.
T25 110.7  11
T30 113.0  10
Diastolic blood pressure (mmHg) T0 68.9  8.8
T5 67.3  9.4
T10 66.0  9.0
T15 64.7  9.4
T20 63.9  9.2
T25 67.8  7.7
T30 67.1  7.8
Heart rate (beats/min) T0 80.2  9.9
T5 63.8  8.7
T10 58.4  8.8
T15 60.3  8.8
T20 62.8  8.6
T25 63.0  5.6
T30 64.1  6.4
a Compared with T0.sympatholytic effects, via intravenous injection or target-
controlled infusion during general anesthesia, can reduce
the dose of intravenous anesthesia [14] or lower the mini-
mum alveolar concentration (MAC) of the inhalational an-
esthetics effectively [15]. It was shown that at the same
level of sedation [according to observer’s assessment of
awareness/sedation (OAA/S)], the BIS score of patients who
received Dex was much lower than that of patients who
received propofol, that is, when the OAA/S score was 4, 3,
and 2, BIS scores induced by propofol were 78, 67, and 57,
respectively, whereas BIS scores induced by Dex were 62,
45, and 39, respectively [16]. The sedative mechanism of
Dex differs from that of propofol, which produces an
anesthetic effect through controlling the receptors of
amino acid neurotransmitters [17,18].
From menarche to menopause, endogenous female sex
hormones (oestrogen, progesterone, follicle-stimulating
hormone and luteinising hormone) are steroid-based sub-
stances released in a cyclical manner. Women experience
the follicular and luteal phases in menstrual cycle due to
cyclic variations of hormone levels in their body. Despite
reproductive function, the related hormones are found to
have vital impacts on the central nervous system [19].
Progesterone and its metabolites are known to exert ef-
fects of sedation, antianxiety, analgesia, and anticonvul-
sant effect [20e23] through direct actions on the GABAA
receptor. Reddy and Apanites [24] infused progesterone
into the peritoneum of mice and rats whose original pro-
gesterone was knocked out and observed the disappear-
ance of their righting reflexes. They found no obvious
difference in the induction dosage between the two groups.
They speculated that the sedative effect was produced by
progesterone and its metabolites rather than by proges-
terone receptors, and similar to propofol, progesterone had20) pa Group L (N Z 20) pa
9 110.6  9.7
.1 0.668 115.5  13.6 0.307
9 0.266 116.7  14.9 0.166
.9 0.133 115.4  13.6 0.247
4 0.064 111.3  14.7 0.876
.5 0.154 111.0  12.5 0.937
.2 0.331 109.3  9.8 0.674
67.4  5.5
0.419 71.1  7.3 0.071
0.206 69.8  10.1 0.374
0.095 68.1  9.0 0.759
0.089 67.0  8.9 0.878
0.662 66.7  9.5 0.760
0.462 66.9  9.6 0.857
76.7  9.3
<0.001 60.1  8.3 <0.001
<0.001 54.7  7.0 <0.001
<0.001 59.0  7.0 <0.001
<0.001 60.7  6.8 <0.001
<0.001 61.1  6.3 <0.001
<0.001 61.9  6.4 <0.001






Peripheral capillary oxygen saturation (SpO2) T0 99.9  0.4 99.9  0.4
T5 99.9  0.4 0.865 99.8  0.5 0.753
T10 98.9  0.4 0.575 98.9  0.4 0.543
T15 99.5  0.5 0.765 99.0  0.8 0.764
T20 99.0  0.8 0.652 99.4  0.5 0.653
T25 98.8  0.8 0.542 99.4  0.3 0.763
T30 99.4  0.4 0.765 99.0  0.6 0.453
Respiratory rate (breaths/min) T0 16.8  1.2 16.8  1.5
T5 16.5  0.9 0.400 16.7  1.2 0.666
T10 16.7  1.6 0.603 17.4  2.1 0.212
T15 17.1  1.3 0.587 17.5  1.9 0.226
T20 16.9  1.4 0.786 17.9  2.2 0.073
T25 16.8  1.3 0.910 17.3  2.1 0.325
T30 16.8  1.5 0.358 17.3  2.1 0.587
End-tidal CO2 pressure
(mmHg)
T0 33.8  1.8 34.5  1.0
T5 32.3  4.2 0.310 33.0  3.8 0.200
T10 33.1  3.0 0.410 32.5  2.8 0.104
T15 32.8  3.0 0.101 33.0  2.5 0.320
T20 32.2  3.5 0.078 32.9  4.0 0.098
T25 32.5  4.1 0.231 33.1  3.9 0.310
T30 33.5  2.1 0.410 34.1  2.5 0.450
a Compared with T0.
Table 4 Bispectral Index changes in the two groups.
Group F Group L pa
No. of cases 20 20




Time for BIS to decrease
to 70
11.3  2.1 9.4  1.3 0.005
No. of cases with BIS
of 60
20 20
Time for BIS to decrease
to 60
14.0  3.6 11.3  2.4 0.021
No. of cases with BIS
of 50
8 15 0.027
The lowest BIS value 55.3  5.5 46.8  6.3 0.006
a Compared with the follicular group.
590 C. Han et al.a positive regulation role through the GABAA receptor.
Comparing the requirement of anesthetized patients in the
follicular phase with those in the luteal phase, Erden et al.
[5] found that the dose of sevoflurane used in the follicular
group (1.55  0.18 MAC-hours) was significantly higher than
that in the luteal group (1.30  0.13 MAC-hours) to reach
the same depth of anesthesia. Fu et al. [25] studied the half
maximal effective concentration (EC50) of propofol for
inducing loss of consciousness in patients who had men-
strual cycles of various lengths and found that the EC50 and
the predicted effect-site concentration at loss of con-
sciousness in patients during the luteal phase were much
lower than in those during the follicular phase. Based onmultiple regression analysis, the authors reported that the
different effects of propofol in patients during different
menstrual cycles were mainly related to the level of pro-
gesterone rather than to other reproductive endocrine
hormones in women. In this study, estrogen levels of both
groups were similar, but their progesterone levels were
different. After intravenous injection of Dex, we found that
the time of BIS in Group L decreased remarkably faster to
70 and 60 than that in Group F. Meanwhile, BIS of 75% of
patients in Group L decreased to 50 within 30 minutes after
Dex infusion, whereas this was the case in only 40% of pa-
tients in Group F. The lowest BIS values in Group L were
lower than those in Group F. Zhou et al. [26] studied the
effects of menstrual cycle on BIS and anesthetic require-
ment in patients receiving preoperative intravenous Dex
following propofol induction, and found that the descent
range of BIS values in the luteal phase group was signifi-
cantly sharper among the four groups at loss of eyelash
reflex. From propofol administration to loss of eyelash re-
flex, BIS scores reached 50 in their study; additionally, in
the luteal phase group, propofol requirements were
significantly less and had the shortest duration from pro-
pofol administration to loss of eyelash reflex. These findings
are in line with the results of our study. We presume that a
certain sedative depth can be achieved more quickly using
a combination of Dex in patients during the luteal phase
because they have higher progesterone level.
Zhou et al. [26] studied the influence of between the
different menstrual cycles and intravenous anesthetics.
However, they reported that their method may confound
the mutual effects of the two sedatives. Although some of
their conclusions were similar to our findings, our research
focused on BIS changes using Dex alone for sedation in
Menstrual phases with dexmedetomidine sedation 591women with different menstrual cycles. As present, the
clinical use of Dex for sedation is widely recognized. For
example, Dex can be used alone for sedation in some
regional anesthesia, and our research may be helpful for
such clinical uses of Dex [27e30].
No other sedation indicators, such as the OAA/S score,
the Ramsay score, or the Richmond Agitation Sedation
Scale, were used in this study except BIS. This is because
the aforementioned scoring systems involve verbal in-
structions and nerve stimuli that might wake the patients
up and interfere with the recording and the accuracy of BIS.
Our study has some limitations. First, the length of the
menstrual cycle depends on the rate and quality of follic-
ular growth and development. We excluded patients whose
menstrual cycle was < 23 days or > 35 days and finally
confirmed patient assignment by measuring the sex hor-
mones levels, thus avoiding the possibility of allocating a
patient to the wrong group. Second, we did not measure
the plasma concentration of Dex, and thus were not able to
objectively reflect the effects of the menstrual cycle on the
sedative effect of Dex.
In this study, we found that the sedative effect of Dex
was more significant in patients during the luteal phase
than during the follicular phase. However, the underlying
mechanisms remain unclear. It is well-known that the
menstrual cycle is characterized by periodic fluctuations of
female sex hormones, which are suggested to be involved in
mechanisms of different anesthetic requirements in the
menstrual phases. Patients in different menstrual cycles
have different sensitivity to anesthetics. Thus, it should be
necessary to consider menstrual cycle in our clinical prac-
tices. With the wide application of Dex in clinical practice,
which is used as an anesthetic adjuvant drug, we suggest
that under the situation of “precision anesthesia,” patients
in different menstrual cycles should be considered indi-
vidually to achieve a proper anesthesia depth.
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